Revelation Biosciences, Inc. – NASDAQ:REVBU

Revelation Biosciences stock price today

$0.29

Revelation Biosciences stock price monthly change

+16.00%
month

Revelation Biosciences key metrics

Market Cap
 N/A
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 -30.94
Revenue
 N/A
EBITDA
 -9.42M
Income
 -8.96M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Revelation Biosciences stock price history

Revelation Biosciences stock forecast

Revelation Biosciences financial statements

Profit Margin

Revelation Biosciences, Inc. (NASDAQ:REVBU): Profit margin
Jun 2023 0 -1.44M
Sep 2023 0 -2.62M
Dec 2023 37.57K -2.20M -5862.84%
Mar 2024 0 -2.68M
REVBU income statement history

Debt to Assets

Revelation Biosciences, Inc. (NASDAQ:REVBU): Debt to assets
Jun 2023 16038838 4.62M 28.83%
Sep 2023 14218520 5.39M 37.98%
Dec 2023 12212609 5.56M 45.57%
Mar 2024 14701610 5.22M 35.56%
REVBU balance sheet history

Cash Flow

Revelation Biosciences, Inc. (NASDAQ:REVBU): Cash Flow
Jun 2023 -1.99M 0 15
Sep 2023 -1.71M 0 0
Dec 2023 -2.00M 0 0
Mar 2024 -2.83M -19.17K 5.41M
REVBU cash flow history

Revelation Biosciences alternative data

Revelation Biosciences
Employees

Revelation Biosciences, Inc. (NASDAQ:REVBU): Employee count
Aug 2023 14
Sep 2023 14
Oct 2023 14
Nov 2023 14
Dec 2023 14
Jan 2024 14
Feb 2024 14
Mar 2024 14
Apr 2024 14
May 2024 14
Jun 2024 14
Jul 2024 14

Revelation Biosciences other data

Frequently Asked Questions (FAQ)

  • What's the price of Revelation Biosciences stock today?

    One share of Revelation Biosciences stock can currently be purchased for approximately $0.29.

  • When is Revelation Biosciences's next earnings date?

    Unfortunately, Revelation Biosciences's (REVBU) next earnings date is currently unknown.

  • Does Revelation Biosciences pay dividends?

    No, Revelation Biosciences does not pay dividends.

  • What is Revelation Biosciences's stock symbol?

    Revelation Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "REVBU".

  • What is Revelation Biosciences's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Revelation Biosciences?

    Shares of Revelation Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Revelation Biosciences have?

    As Jul 2024, Revelation Biosciences employs 14 workers.

  • When Revelation Biosciences went public?

    Revelation Biosciences, Inc. is publicly traded company for more then 4 years since IPO on 8 Oct 2020.

  • What is Revelation Biosciences's official website?

    The official website for Revelation Biosciences is revbiosciences.com.

  • Where are Revelation Biosciences's headquarters?

    Revelation Biosciences is headquartered at 4660 La Jolla Village Drive, San Diego, CA.

  • How can i contact Revelation Biosciences?

    Revelation Biosciences's mailing address is 4660 La Jolla Village Drive, San Diego, CA and company can be reached via phone at +65 08003717.

Revelation Biosciences company profile:

Revelation Biosciences, Inc.

revbiosciences.com
Exchange:

NASDAQ

Full time employees:

14

Industry:

Biotechnology

Sector:

Healthcare

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

+65 08003717
4660 La Jolla Village Drive
San Diego, CA 92122

CIK: 0001810560
:
: